Skip to Main Navigation
Skip to Page Content

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/8911

Hydrochlorothiazide: Target Organs and Levels of Evidence for TR-357

Toxicology and Carcinogenesis Studies of Hydrochlorothiazide (CASRN 58-93-5) in F344/N Rats and B6C3F1 Mice (Feed Studies)

Chemical (Study Title)
CASRN		Peer Review DateRoute/Exposure LevelsStudy Laboratory
Hydrochlorothiazide
58-93-5		04/18/1988Dosed-Feed
R: 0,250,500,2000 PPM/60 PER GROUP, M: 0,2500,5000 PPM/50 PER GROUP		SRI International

Levels of Evidence

Male Rats: No Evidence
TypeOrgan/Tissue (Lesion)
Non-Neoplastic Lesions
  • KIDNEY: CHRONIC RENAL DISEASE AND SECONDARY LESIONS
Female Rats: No Evidence
TypeOrgan/Tissue (Lesion)
Non-Neoplastic Lesions
  • KIDNEY: CHRONIC RENAL DISEASE AND SECONDARY LESIONS
Male Mice: Equivocal Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Liver: ADENOMA 3/48 8/49 14/50 OR CARCINOMA 4/48 4/49 9/50 COMBINED 7/48 10/49 21/50
Female Mice: No Evidence